Graft Polymer (UK) PLC hailed as a major milestone the award of a hazard analysis and critical control point (HACCP) certificate to its research and development facility in Slovenia.
The sign-off will allow its GraftBio operation to enter the business-to-consumer market, ‘thereby introducing a further revenue stream to its business", investors were told.
Graft said the intention now was to "create a strong reputation as a manufacturer of quality and safe food supplements".
“We intend to develop the GraftBio division in the international market with the development of drug delivery systems for different applications dependent on customers' and consumers' needs,” said chief executive, Victor Bolduev.